Jun-18-2025 | 10:50 Hrs IST

Glenmark Pharmaceuticals is trading higher at Rate RS 1659.35, up by 5.60 points or 0.34% from its previous close of Rate RS 1653.75 on the BSE.

The stock opened at Rate RS 1653.15 and has touched an intraday high of Rate RS 1661.95 and a low of Rate RS 1637.60. So far, 3,425 shares have been traded on the counter.

A part of the BSE Group 'A', Glenmark has a face value of Rate RS 1. It has recorded a 52-week high of Rate RS 1830.05 on October 15, 2024, and a 52-week low of Rate RS 1199.95 on June 26, 2024. Over the last week, it has fluctuated between a high of Rate RS 1690.95 and a low of Rate RS 1605.50. The company currently holds a market capitalization of Rate RS 46900.36 crore.

The promoter holding in the company stands at 46.65%, while institutional and non-institutional investors hold 37.80% and 15.56%, respectively.

The stock’s movement comes after Glenmark Pharmaceuticals announced the conclusion of a Good Manufacturing Practice (GMP) inspection by the United States Food & Drug Administration (USFDA) at its Monroe, North Carolina facility. Conducted between June 09 and June 17, 2025, the inspection resulted in a Form 483 with five procedural observations. Importantly, no data integrity issues were found.

Glenmark has stated that it will work closely with the USFDA to address the observations and submit a response within the stipulated timeframe.

Glenmark Pharmaceuticals is a global, research-led pharmaceutical company with strong footprints in Generics, Specialty, and OTC segments, operating in over 50 countries worldwide.